Product Information
- 4-(3-[5-Chloro-1-(diphenylmethyl)-2-[2-(((2-(trifluoromethyl)benzyl)sulfonyl)amino)ethyl]-1H-indole-3-yl]propyl)benzoic acid
Giripladib is an anti-angiogenic drug that inhibits the action of metalloproteases. The drug is a competitive inhibitor of the enzyme, and prevents proteolysis of the extracellular matrix by binding to thrombin receptor. Giripladib also inhibits the production of prostaglandins and cytokines, which are important mediators in inflammatory diseases. Giripladib has been shown to be effective in animal models for pain, as well as in mouse tumor models. It also has cytostatic and anti-cancer effects on human cells, inhibiting cellular proliferation and inducing apoptosis.